Compare Ishares Msci Brazil ETF (EWZ) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Ishares Msci Brazil ETF trades at $41.99 (market cap $13.28B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Ishares Msci Brazil ETF is far larger — about 13.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EWZ | MRVI | |
|---|---|---|
Market Cap | $13.28B | $977.37M |
Volume | 59,308,012 | 2,742,564 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.54 | $9.00 |
52-Week Low | $29.24 | $2.83 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.87, down 1.54% today, with a bullish technical signal driven by moving averages but showing overbought RSI levels. The ETF is attracting significant attention due to Brazil's upcoming October election, with institutional investors accumulating positions through call options. Recent news highlights EWZ as a diversification tool against U.S. tech concentration and potential beneficiary of Brazilian economic policies.
The outlook for EWZ hinges on Brazil's political election outcome and commodity trends, offering asymmetric upside but facing currency and political volatility risks. Wall Street positioning suggests optimism, though investors must weigh the ETF's higher expense ratio against alternatives like FLBR for Brazilian exposure.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
